| First Author | Chang HM | Year | 2014 |
| Journal | PLoS One | Volume | 9 |
| Issue | 8 | Pages | e105299 |
| PubMed ID | 25170969 | Mgi Jnum | J:221071 |
| Mgi Id | MGI:5637886 | Doi | 10.1371/journal.pone.0105299 |
| Citation | Chang HM, et al. (2014) The FYVE domain of Smad Anchor for Receptor Activation (SARA) is required to prevent skin carcinogenesis, but not in mouse development. PLoS One 9(8):e105299 |
| abstractText | Smad Anchor for Receptor Activation (SARA) has been reported as a critical role in TGF-beta signal transduction by recruiting non-activated Smad2/3 to the TGF-beta receptor and ensuring appropriate subcellular localization of the activated receptor-bound complex. However, controversies still exist in previous reports. In this study, we describe the expression of two SARA isoforms, SARA1 and SARA2, in mice and report the generation and characterization of SARA mutant mice with FYVE domain deletion. SARA mutant mice developed normally and showed no gross abnormalities. Further examination showed that the TGF-beta signaling pathway was indeed altered in SARA mutant mice, with the downregulation of Smad2 protein expression. The decreasing expression of Smad2 was caused by enhancing Smurf2-mediated proteasome degradation pathway. However, the internalization of TGF-beta receptors into the early endosome was not affected in SARA mutant mouse embryonic fibroblasts (MEFs). Moreover, the downregulation of Smad2 in SARA mutant MEFs was not sufficient to disrupt the diverse cellular biological functions of TGF-beta signaling, including growth inhibition, apoptosis, senescence, and the epithelial-to-mesenchymal transition. Our results indicate that SARA is not involved in the activation process of TGF-beta signal transduction. Using a two-stage skin chemical carcinogenesis assay, we found that the loss of SARA promoted skin tumor formation and malignant progression. Our data suggest a protective role of SARA in skin carcinogenesis. |
